Dawnrays Pharmaceutical (Holdings) Limited

SEHK:2348 Stock Report

Market Cap: HK$1.8b

Dawnrays Pharmaceutical (Holdings) Past Earnings Performance

Past criteria checks 4/6

Dawnrays Pharmaceutical (Holdings) has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 5.4% per year. Dawnrays Pharmaceutical (Holdings)'s return on equity is 17.1%, and it has net margins of 52.2%.

Key information

13.1%

Earnings growth rate

14.3%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate5.4%
Return on equity17.1%
Net Margin52.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

Sep 21
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

Sep 21
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 11
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

May 25
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Apr 22
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Apr 08
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Mar 25
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Aug 30
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

May 26
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Apr 04
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 19
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Sep 22
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Sep 12
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Aug 29
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Feb 28
Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Feb 07
Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Jan 14
Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Dec 22
Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Dec 09
What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Nov 23
Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Revenue & Expenses Breakdown

How Dawnrays Pharmaceutical (Holdings) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:2348 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,079563255104
31 Mar 241,11544525897
31 Dec 231,15132626091
30 Sep 231,22838426086
30 Jun 231,30444226080
31 Mar 231,29140026280
31 Dec 221,27835826579
30 Sep 221,22936124974
30 Jun 221,18036323469
31 Mar 221,17336123068
31 Dec 211,16535822667
30 Sep 211,15533221365
30 Jun 211,14430520063
31 Mar 211,08428718261
31 Dec 201,02426816458
30 Sep 2098625116940
30 Jun 2094823517523
31 Mar 2094924517811
31 Dec 199502551820
30 Sep 199462721880
30 Jun 199432881940
31 Mar 199462961920
31 Dec 189493041900
30 Sep 189473071840
30 Jun 189463101780
31 Mar 189143021740
31 Dec 178822931710
30 Sep 178612881710
30 Jun 178392831720
31 Mar 178322751680
31 Dec 168242661640
30 Sep 168702731590
30 Jun 169152791540
31 Mar 169502911620
31 Dec 159853021690
30 Sep 159242801690
30 Jun 158632581680
31 Mar 158232311640
31 Dec 147842051600
30 Sep 148311911680
30 Jun 148781771760
31 Mar 148961651750

Quality Earnings: 2348 has a high level of non-cash earnings.

Growing Profit Margin: 2348's current net profit margins (52.2%) are higher than last year (33.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2348's earnings have grown by 13.1% per year over the past 5 years.

Accelerating Growth: 2348's earnings growth over the past year (27.3%) exceeds its 5-year average (13.1% per year).

Earnings vs Industry: 2348 earnings growth over the past year (27.3%) exceeded the Pharmaceuticals industry 9.4%.

Return on Equity

High ROE: 2348's Return on Equity (17.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 12:28
End of Day Share Price 2025/01/28 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dawnrays Pharmaceutical (Holdings) Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wing-Tai NgChina Galaxy International Securities (Hong Kong)
Wai Chak YuenCinda International Research Limited
Iris WangCredit Suisse